Taro Announces Results of Its Annual General Meeting of Shareholders

HAWTHORNE, N.Y.--()--Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) announced that the Company held its annual general meeting of shareholders on December 22, 2014, at the offices of Meitar Liquornik Geva Leshem Tal, located at 16 Abba Hillel Road, Gallery Floor, Ramat Gan (the “Annual General Meeting”).

At the Annual General Meeting, the following resolutions were approved (i) five directors (Dilip Shanghvi, Kal Sundaram, Sudhir Valia, James Kedrowski and Dov Pekelman) were re-elected to the Company’s Board of Directors to serve until the close of the next annual general meeting of shareholders, and (ii) Ziv Haft, Certified Public Accountants (Israel), a BDO member firm, was appointed as the Company’s independent auditors until the close of the next annual general meeting of shareholders of the Company and the Audit Committee of the Company and the Board of Directors were authorized to fix their remuneration, in accordance with the volume and nature of their services.

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

Contacts

Taro Pharmaceutical Industries Ltd.
William J. Coote, 914-345-9001
William.Coote@taro.com

Contacts

Taro Pharmaceutical Industries Ltd.
William J. Coote, 914-345-9001
William.Coote@taro.com